Research progress of the engagement of inorganic nanomaterials in cancer immunotherapy

Drug Deliv. 2022 Dec;29(1):1914-1932. doi: 10.1080/10717544.2022.2086940.

Abstract

Cancer has attracted widespread attention from scientists for its high morbidity and mortality, posing great threats to people's health. Cancer immunotherapy with high specificity, low toxicity as well as triggering systemic anti-tumor response has gradually become common in clinical cancer treatment. However, due to the insufficient immunogenicity of tumor antigens peptides, weak ability to precisely target tumor sites, and the formation of tumor immunosuppressive microenvironment, the efficacy of immunotherapy is often limited. In recent years, the emergence of inorganic nanomaterials makes it possible for overcoming the limitations mentioned above. With self-adjuvant properties, high targeting ability, and good biocompatibility, the inorganic nanomaterials have been integrated with cancer immunotherapy and significantly improved the therapeutic effects.

Keywords: Inorganic nanomaterials; cancer vaccine; chemoimmunotherapy; tumor immunity; tumor microenvironment.

MeSH terms

  • Adjuvants, Immunologic
  • Humans
  • Immunotherapy
  • Nanostructures* / chemistry
  • Neoplasms* / drug therapy
  • Tumor Microenvironment

Substances

  • Adjuvants, Immunologic

Grants and funding

This work was supported by the Clinical Research Project of Health Industry of Shanghai Municipal Health Commission [Grant No.202140407], the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai [Grant No. PWR12018-05], and the Open Funds of Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province [Grant No. KFJJ-202007].